Dept. of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada; Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada; Dept. of Urology, NYU Langone Health, New York, NY.
Dept. of Pathology, NYU Langone Health, New York, NY.
Urol Oncol. 2025 Jan;43(1):64.e19-64.e25. doi: 10.1016/j.urolonc.2024.06.023. Epub 2024 Aug 10.
In-field or in-margin recurrence after partial gland cryosurgical ablation (PGCA) of prostate cancer (PCa) remains a limitation of the paradigm. Stimulated Raman histology (SRH) is a novel microscopic technique allowing real time, label-free, high-resolution microscopic images of unprocessed, un-sectioned tissue which can be interpreted by humans or artificial intelligence (AI). We evaluated surgical team and AI interpretation of SRH for real-time pathologic feedback in the planning and treatment of PCa with PGCA.
About 12 participants underwent prostate mapping biopsies during PGCA of their PCa between January and June 2022. Prostate biopsies were immediately scanned in a SRH microscope at 20 microns depth using 2 Raman shifts to create SRH images which were interpreted by the surgical team intraoperatively to guide PGCA, and retrospectively assessed by AI. The cores were then processed, hematoxylin and eosin stained as per normal pathologic protocols and used for ground truth pathologic assessment.
Surgical team interpretation of SRH intraoperatively revealed 98.1% accuracy, 100% sensitivity, 97.3% specificity for identification of PCa, while AI showed a 97.9% accuracy, 100% sensitivity and 97.5% specificity for identification of clinically significant PCa. 3 participants' PGCA treatments were modified after SRH visualized PCa adjacent to an expected MRI predicted tumor margin or at an untreated cryosurgical margin.
SRH allows for accurate rapid identification of PCa in PB by a surgical team interpretation or AI. PCa tumor mapping and margin assessment during PGCA appears to be feasible and accurate. Further studies evaluating impact on clinical outcomes are warranted.
前列腺癌(PCa)经部分腺体冷冻消融(PGCA)后出现场内或场缘复发仍然是该方法的局限性。受激拉曼组织学(SRH)是一种新的微观技术,允许对未经处理、未经切片的组织进行实时、无标记、高分辨率的微观成像,人类或人工智能(AI)均可对其进行解释。我们评估了手术团队和 AI 对 SRH 的解释,以在 PGCA 治疗 PCa 时进行实时病理反馈。
大约 12 名参与者在 2022 年 1 月至 6 月期间接受了 PGCA 治疗其 PCa 期间接受了前列腺图谱活检。使用 2 个拉曼位移,立即在 SRH 显微镜下以 20 微米的深度扫描前列腺活检,以创建 SRH 图像,这些图像由手术团队在手术过程中进行解释,以指导 PGCA,并由 AI 进行回顾性评估。然后,将标本按常规病理程序进行处理,用苏木精和伊红染色,并用于地面真实病理评估。
手术团队术中对 SRH 的解释显示,PCa 的识别准确率为 98.1%,灵敏度为 100%,特异性为 97.3%,而 AI 显示,识别临床显著 PCa 的准确率为 97.9%,灵敏度为 100%,特异性为 97.5%。3 名参与者的 PGCA 治疗在 SRH 可视化显示 PGCA 紧邻预期 MRI 预测的肿瘤边缘或未治疗的冷冻边缘后进行了修改。
SRH 允许手术团队或 AI 快速准确地识别 PB 中的 PCa。PGCA 期间的 PCa 肿瘤绘图和边缘评估似乎是可行且准确的。需要进一步研究评估其对临床结果的影响。